<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom" xmlns:content="http://purl.org/rss/1.0/modules/content/" xmlns:dc="http://purl.org/dc/elements/1.1/">
<channel>
<title>心血管高分期刊</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;v=2.18.0.post9+e462414&amp;utm_medium=rss&amp;utm_source=Chrome&amp;utm_campaign=pubmed-2&amp;ff=20240504001123
    <description>心血管高分期刊: Latest results from PubMed</description>
<atom:link href="https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;v=2.18.0.post9+e462414&amp;utm_medium=rss&amp;utm_source=Chrome&amp;utm_campaign=pubmed-2&amp;ff=20240504001123" rel="self"></atom:link>
<docs>http://www.rssboard.org/rss-specification</docs>
<generator>PubMed RSS feeds (2.18.0.post9+e462414)</generator>
<language>en</language>
<lastbuilddate>Sat, 04 May 2024 04:11:23 +0000</lastbuilddate>
<pubDate>Fri, 03 May 2024 06:00:00 -0400</pubDate>
<ttl>120</ttl>
<item>
<title>A very rare complication: Amplatzer Septal Occluder dislodgement 6 days later under Ecpella</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38701047/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240504001123&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 May 3:ehae238. doi: 10.1093/eurheartj/ehae238. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38701047/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240504001123&v=2.18.0.post9+e462414">38701047</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae238>10.1093/eurheartj/ehae238</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38701047</guid>
<pubDate>Fri, 03 May 2024 06:00:00 -0400</pubDate>
<dc:creator>Yu-Chuan Chuang</dc:creator>
<dc:creator>Tsun-Jui Liu</dc:creator>
<dc:creator>Wei-Wen Lin</dc:creator>
<dc:date>2024-05-03</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>A very rare complication: Amplatzer Septal Occluder dislodgement 6 days later under Ecpella</dc:title>
<dc:identifier>pmid:38701047</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae238</dc:identifier>
</item>
<item>
<title>Paradoxical progress of function and fibrosis in FLNC cardiomyopathy after therapy</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38701022/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240504001123&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 May 3:ehae241. doi: 10.1093/eurheartj/ehae241. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38701022/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240504001123&v=2.18.0.post9+e462414">38701022</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae241>10.1093/eurheartj/ehae241</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38701022</guid>
<pubDate>Fri, 03 May 2024 06:00:00 -0400</pubDate>
<dc:creator>Yangjie Li</dc:creator>
<dc:creator>Yuanwei Xu</dc:creator>
<dc:creator>Yucheng Chen</dc:creator>
<dc:date>2024-05-03</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Paradoxical progress of function and fibrosis in FLNC cardiomyopathy after therapy</dc:title>
<dc:identifier>pmid:38701022</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae241</dc:identifier>
</item>
<item>
<title>Abdominal aortic penetration caused by an incidentally discovered inferior vena cava filter</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38701019/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240504001123&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 May 3:ehae275. doi: 10.1093/eurheartj/ehae275. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38701019/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240504001123&v=2.18.0.post9+e462414">38701019</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae275>10.1093/eurheartj/ehae275</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38701019</guid>
<pubDate>Fri, 03 May 2024 06:00:00 -0400</pubDate>
<dc:creator>Jiarong Wang</dc:creator>
<dc:creator>Yuhang Zhou</dc:creator>
<dc:creator>Tiehao Wang</dc:creator>
<dc:date>2024-05-03</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Abdominal aortic penetration caused by an incidentally discovered inferior vena cava filter</dc:title>
<dc:identifier>pmid:38701019</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae275</dc:identifier>
</item>
<item>
<title>Cement arrow in the heart: an unusual vertebroplasty complication</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38701007/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240504001123&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 May 3:ehae237. doi: 10.1093/eurheartj/ehae237. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38701007/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240504001123&v=2.18.0.post9+e462414">38701007</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae237>10.1093/eurheartj/ehae237</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38701007</guid>
<pubDate>Fri, 03 May 2024 06:00:00 -0400</pubDate>
<dc:creator>Xiaolan Feng</dc:creator>
<dc:creator>Qingzhong Zhou</dc:creator>
<dc:date>2024-05-03</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Cement arrow in the heart: an unusual vertebroplasty complication</dc:title>
<dc:identifier>pmid:38701007</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae237</dc:identifier>
</item>
<item>
<title>Discordance among apoB, non-high-density lipoprotein cholesterol, and triglycerides: implications for cardiovascular prevention</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38700053/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240504001123&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: High variability of apoB at individual levels of LDL-C, non-HDL-C, and triglycerides coupled with meaningful differences in 10-year ASCVD rates and significant residual information contained in apoB for prediction of new-onset ASCVD events demonstrate that LDL-C, non-HDL-C, and triglycerides are not adequate proxies for apoB in clinical care.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 May 3:ehae258. doi: 10.1093/eurheartj/ehae258. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND AND AIMS: Despite growing evidence that apolipoprotein B (apoB) is the most accurate marker of atherosclerotic cardiovascular disease (ASCVD) risk, its adoption in clinical practice has been low. This investigation sought to determine whether low-density lipoprotein cholesterol (LDL-C), non-high-density lipoprotein cholesterol (HDL-C), and triglycerides are sufficient for routine cardiovascular care.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: A sample of 293 876 UK Biobank adults (age: 40-73 years, 42% men), free of cardiovascular disease, with a median follow-up for new-onset ASCVD of 11 years was included. Distribution of apoB at pre-specified levels of LDL-C, non-HDL-C, and triglycerides was examined graphically, and 10-year ASCVD event rates were compared for high vs. low apoB. Residuals of apoB were constructed after regressing apoB on LDL-C, non-HDL-C, and log-transformed triglycerides and used as predictors in a proportional hazards regression model for new-onset ASCVD adjusted for standard risk factors, including HDL-C.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: ApoB was highly correlated with LDL-C and non-HDL-C (Pearson's r = .96, P &lt; .001 for both) but less so with log triglycerides (r = .42, P &lt; .001). However, apoB ranges necessary to capture 95% of all observations at pre-specified levels of LDL-C, non-HDL-C, or triglycerides were wide, spanning 85.8-108.8 md/dL when LDL-C 130 mg/dL, 88.3-112.4 mg/dL when non-HDL-C 160 mg/dL, and 67.8-147.4 md/dL when triglycerides 115 mg/dL. At these levels (±10 mg/dL), 10-year ASCVD rates for apoB above mean + 1 SD vs. below mean - 1 SD were 7.3 vs. 4.0 for LDL-C, 6.4 vs. 4.6 for non-HDL-C, and 7.0 vs. 4.6 for triglycerides (all P &lt; .001). With 19 982 new-onset ASCVD events on follow-up, in the adjusted model, residual apoB remained statistically significant after accounting for LDL-C and HDL-C (hazard ratio 1.06, 95% confidence interval 1.0-1.07), after accounting for non-HDL-C and HDL-C (hazard ratio 1.04, 95% confidence interval 1.03-1.06), and after accounting for triglycerides and HDL-C (hazard ratio 1.13, 95% confidence interval 1.12-1.15). None of the residuals of LDL-C, non-HDL-C, or of log triglycerides remained significant when apoB was included in the model.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: High variability of apoB at individual levels of LDL-C, non-HDL-C, and triglycerides coupled with meaningful differences in 10-year ASCVD rates and significant residual information contained in apoB for prediction of new-onset ASCVD events demonstrate that LDL-C, non-HDL-C, and triglycerides are not adequate proxies for apoB in clinical care.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38700053/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240504001123&v=2.18.0.post9+e462414">38700053</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae258>10.1093/eurheartj/ehae258</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38700053</guid>
<pubDate>Fri, 03 May 2024 06:00:00 -0400</pubDate>
<dc:creator>Allan D Sniderman</dc:creator>
<dc:creator>Line Dufresne</dc:creator>
<dc:creator>Karol M Pencina</dc:creator>
<dc:creator>Selin Bilgic</dc:creator>
<dc:creator>George Thanassoulis</dc:creator>
<dc:creator>Michael J Pencina</dc:creator>
<dc:date>2024-05-03</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Discordance among apoB, non-high-density lipoprotein cholesterol, and triglycerides: implications for cardiovascular prevention</dc:title>
<dc:identifier>pmid:38700053</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae258</dc:identifier>
</item>
<item>
<title>Stress and cardiovascular disease: an update</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38698183/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240504001123&amp;v=2.18.0.post9+e462414
      <description>Psychological stress is generally accepted to be associated with an increased risk of cardiovascular disease (CVD), but results have varied in terms of how stress is measured and the strength of the association. Additionally, the mechanisms and potential causal links have remained speculative despite decades of research. The physiological responses to stress are well characterized, but their contribution to the development and progression of CVD has received little attention in empirical...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Nat Rev Cardiol. 2024 May 2. doi: 10.1038/s41569-024-01024-y. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Psychological stress is generally accepted to be associated with an increased risk of cardiovascular disease (CVD), but results have varied in terms of how stress is measured and the strength of the association. Additionally, the mechanisms and potential causal links have remained speculative despite decades of research. The physiological responses to stress are well characterized, but their contribution to the development and progression of CVD has received little attention in empirical studies. Evidence suggests that physiological responses to stress have a fundamental role in the risk of CVD and that haemodynamic, vascular and immune perturbations triggered by stress are especially implicated. Stress response physiology is regulated by the corticolimbic regions of the brain, which have outputs to the autonomic nervous system. Variation in these regulatory pathways might explain interindividual differences in vulnerability to stress. Dynamic perturbations in autonomic, immune and vascular functions are probably also implicated as CVD risk mechanisms of chronic, recurring and cumulative stressful exposures, but more data are needed from prospective studies and from assessments in real-life situations. Psychological assessment remains insufficiently recognized in clinical care and prevention. Although stress-reduction interventions might mitigate perceived stress levels and potentially reduce cardiovascular risk, more data from randomized trials are needed.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38698183/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240504001123&v=2.18.0.post9+e462414">38698183</a> | DOI:<a href=https://doi.org/10.1038/s41569-024-01024-y>10.1038/s41569-024-01024-y</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38698183</guid>
<pubDate>Thu, 02 May 2024 06:00:00 -0400</pubDate>
<dc:creator>Viola Vaccarino</dc:creator>
<dc:creator>J Douglas Bremner</dc:creator>
<dc:date>2024-05-02</dc:date>
<dc:source>Nature reviews. Cardiology</dc:source>
<dc:title>Stress and cardiovascular disease: an update</dc:title>
<dc:identifier>pmid:38698183</dc:identifier>
<dc:identifier>doi:10.1038/s41569-024-01024-y</dc:identifier>
</item>
<item>
<title>Reply to 'Screening for Helicobacter pylori infection in patients with cardiovascular and gastrointestinal disease'</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38698182/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240504001123&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Nat Rev Cardiol. 2024 May 2. doi: 10.1038/s41569-024-01029-7. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38698182/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240504001123&v=2.18.0.post9+e462414">38698182</a> | DOI:<a href=https://doi.org/10.1038/s41569-024-01029-7>10.1038/s41569-024-01029-7</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38698182</guid>
<pubDate>Thu, 02 May 2024 06:00:00 -0400</pubDate>
<dc:creator>Azita H Talasaz</dc:creator>
<dc:creator>Behnood Bikdeli</dc:creator>
<dc:date>2024-05-02</dc:date>
<dc:source>Nature reviews. Cardiology</dc:source>
<dc:title>Reply to 'Screening for Helicobacter pylori infection in patients with cardiovascular and gastrointestinal disease'</dc:title>
<dc:identifier>pmid:38698182</dc:identifier>
<dc:identifier>doi:10.1038/s41569-024-01029-7</dc:identifier>
</item>
<item>
<title>Screening for Helicobacter pylori infection in patients with cardiovascular and gastrointestinal disease</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38698181/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240504001123&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Nat Rev Cardiol. 2024 May 2. doi: 10.1038/s41569-024-01028-8. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38698181/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240504001123&v=2.18.0.post9+e462414">38698181</a> | DOI:<a href=https://doi.org/10.1038/s41569-024-01028-8>10.1038/s41569-024-01028-8</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38698181</guid>
<pubDate>Thu, 02 May 2024 06:00:00 -0400</pubDate>
<dc:creator>Jonatan Wärme</dc:creator>
<dc:creator>Martin O Sundqvist</dc:creator>
<dc:creator>Stefan James</dc:creator>
<dc:creator>Robin Hofmann</dc:creator>
<dc:date>2024-05-02</dc:date>
<dc:source>Nature reviews. Cardiology</dc:source>
<dc:title>Screening for Helicobacter pylori infection in patients with cardiovascular and gastrointestinal disease</dc:title>
<dc:identifier>pmid:38698181</dc:identifier>
<dc:identifier>doi:10.1038/s41569-024-01028-8</dc:identifier>
</item>
<item>
<title>RNA aggregates harness the danger response for potent cancer immunotherapy</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38697107/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240504001123&amp;v=2.18.0.post9+e462414
      <description>Cancer immunotherapy remains limited by poor antigenicity and a regulatory tumor microenvironment (TME). Here, we create "onion-like" multi-lamellar RNA lipid particle aggregates (LPAs) to substantially enhance the payload packaging and immunogenicity of tumor mRNA antigens. Unlike current mRNA vaccine designs that rely on payload packaging into nanoparticle cores for Toll-like receptor engagement in immune cells, systemically administered RNA-LPAs activate RIG-I in stromal cells, eliciting...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Cell</b>. 2024 Apr 26:S0092-8674(24)00398-2. doi: 10.1016/j.cell.2024.04.003. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Cancer immunotherapy remains limited by poor antigenicity and a regulatory tumor microenvironment (TME). Here, we create "onion-like" multi-lamellar RNA lipid particle aggregates (LPAs) to substantially enhance the payload packaging and immunogenicity of tumor mRNA antigens. Unlike current mRNA vaccine designs that rely on payload packaging into nanoparticle cores for Toll-like receptor engagement in immune cells, systemically administered RNA-LPAs activate RIG-I in stromal cells, eliciting massive cytokine/chemokine response and dendritic cell/lymphocyte trafficking that provokes cancer immunogenicity and mediates rejection of both early- and late-stage murine tumor models. In client-owned canines with terminal gliomas, RNA-LPAs improved survivorship and reprogrammed the TME, which became "hot" within days of a single infusion. In a first-in-human trial, RNA-LPAs elicited rapid cytokine/chemokine release, immune activation/trafficking, tissue-confirmed pseudoprogression, and glioma-specific immune responses in glioblastoma patients. These data support RNA-LPAs as a new technology that simultaneously reprograms the TME while eliciting rapid and enduring cancer immunotherapy.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38697107/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240504001123&v=2.18.0.post9+e462414">38697107</a> | DOI:<a href=https://doi.org/10.1016/j.cell.2024.04.003>10.1016/j.cell.2024.04.003</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38697107</guid>
<pubDate>Thu, 02 May 2024 06:00:00 -0400</pubDate>
<dc:creator>Hector R Mendez-Gomez</dc:creator>
<dc:creator>Anna DeVries</dc:creator>
<dc:creator>Paul Castillo</dc:creator>
<dc:creator>Christina von Roemeling</dc:creator>
<dc:creator>Sadeem Qdaisat</dc:creator>
<dc:creator>Brian D Stover</dc:creator>
<dc:creator>Chao Xie</dc:creator>
<dc:creator>Frances Weidert</dc:creator>
<dc:creator>Chong Zhao</dc:creator>
<dc:creator>Rachel Moor</dc:creator>
<dc:creator>Ruixuan Liu</dc:creator>
<dc:creator>Dhruvkumar Soni</dc:creator>
<dc:creator>Elizabeth Ogando-Rivas</dc:creator>
<dc:creator>Jonathan Chardon-Robles</dc:creator>
<dc:creator>James McGuiness</dc:creator>
<dc:creator>Dingpeng Zhang</dc:creator>
<dc:creator>Michael C Chung</dc:creator>
<dc:creator>Christiano Marconi</dc:creator>
<dc:creator>Stephen Michel</dc:creator>
<dc:creator>Arnav Barpujari</dc:creator>
<dc:creator>Gabriel W Jobin</dc:creator>
<dc:creator>Nagheme Thomas</dc:creator>
<dc:creator>Xiaojie Ma</dc:creator>
<dc:creator>Yodarlynis Campaneria</dc:creator>
<dc:creator>Adam Grippin</dc:creator>
<dc:creator>Aida Karachi</dc:creator>
<dc:creator>Derek Li</dc:creator>
<dc:creator>Bikash Sahay</dc:creator>
<dc:creator>Leighton Elliott</dc:creator>
<dc:creator>Timothy P Foster</dc:creator>
<dc:creator>Kirsten E Coleman</dc:creator>
<dc:creator>Rowan J Milner</dc:creator>
<dc:creator>W Gregory Sawyer</dc:creator>
<dc:creator>John A Ligon</dc:creator>
<dc:creator>Eugenio Simon</dc:creator>
<dc:creator>Brian Cleaver</dc:creator>
<dc:creator>Kristine Wynne</dc:creator>
<dc:creator>Marcia Hodik</dc:creator>
<dc:creator>Annette M Molinaro</dc:creator>
<dc:creator>Juan Guan</dc:creator>
<dc:creator>Patrick Kellish</dc:creator>
<dc:creator>Andria Doty</dc:creator>
<dc:creator>Ji-Hyun Lee</dc:creator>
<dc:creator>Tara Massini</dc:creator>
<dc:creator>Jesse L Kresak</dc:creator>
<dc:creator>Jianping Huang</dc:creator>
<dc:creator>Eugene I Hwang</dc:creator>
<dc:creator>Cassie Kline</dc:creator>
<dc:creator>Sheila Carrera-Justiz</dc:creator>
<dc:creator>Maryam Rahman</dc:creator>
<dc:creator>Sebastian Gatica</dc:creator>
<dc:creator>Sabine Mueller</dc:creator>
<dc:creator>Michael Prados</dc:creator>
<dc:creator>Ashley P Ghiaseddin</dc:creator>
<dc:creator>Natalie L Silver</dc:creator>
<dc:creator>Duane A Mitchell</dc:creator>
<dc:creator>Elias J Sayour</dc:creator>
<dc:date>2024-05-02</dc:date>
<dc:source>Cell</dc:source>
<dc:title>RNA aggregates harness the danger response for potent cancer immunotherapy</dc:title>
<dc:identifier>pmid:38697107</dc:identifier>
<dc:identifier>doi:10.1016/j.cell.2024.04.003</dc:identifier>
</item>
<item>
<title>A transcription factor atlas of directed differentiation</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38697106/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240504001123&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Cell</b>. 2024 May 1:S0092-8674(24)00464-1. doi: 10.1016/j.cell.2024.04.038. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38697106/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240504001123&v=2.18.0.post9+e462414">38697106</a> | DOI:<a href=https://doi.org/10.1016/j.cell.2024.04.038>10.1016/j.cell.2024.04.038</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38697106</guid>
<pubDate>Thu, 02 May 2024 06:00:00 -0400</pubDate>
<dc:creator>Julia Joung</dc:creator>
<dc:creator>Sai Ma</dc:creator>
<dc:creator>Tristan Tay</dc:creator>
<dc:creator>Kathryn R Geiger-Schuller</dc:creator>
<dc:creator>Paul C Kirchgatterer</dc:creator>
<dc:creator>Vanessa K Verdine</dc:creator>
<dc:creator>Baolin Guo</dc:creator>
<dc:creator>Mario A Arias-Garcia</dc:creator>
<dc:creator>William E Allen</dc:creator>
<dc:creator>Ankita Singh</dc:creator>
<dc:creator>Olena Kuksenko</dc:creator>
<dc:creator>Omar O Abudayyeh</dc:creator>
<dc:creator>Jonathan S Gootenberg</dc:creator>
<dc:creator>Zhanyan Fu</dc:creator>
<dc:creator>Rhiannon K Macrae</dc:creator>
<dc:creator>Jason D Buenrostro</dc:creator>
<dc:creator>Aviv Regev</dc:creator>
<dc:creator>Feng Zhang</dc:creator>
<dc:date>2024-05-02</dc:date>
<dc:source>Cell</dc:source>
<dc:title>A transcription factor atlas of directed differentiation</dc:title>
<dc:identifier>pmid:38697106</dc:identifier>
<dc:identifier>doi:10.1016/j.cell.2024.04.038</dc:identifier>
</item>
<item>
<title>Deficiency of the Deubiquitinase UCHL1 Attenuates Pulmonary Arterial Hypertension</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38695173/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240504001123&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: Our findings suggest that UCHL1 deficiency results in PAH attenuation by means of reduced AKT1, highlighting a novel therapeutic pathway in PAH.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 May 2. doi: 10.1161/CIRCULATIONAHA.123.065304. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: The ubiquitin-proteasome system regulates protein degradation and the development of pulmonary arterial hypertension (PAH), but knowledge about the role of deubiquitinating enzymes in this process is limited. UCHL1 (ubiquitin carboxyl-terminal hydrolase 1), a deubiquitinase, has been shown to reduce AKT1 (AKT serine/threonine kinase 1) degradation, resulting in higher levels. Given that AKT1 is pathological in pulmonary hypertension, we hypothesized that UCHL1 deficiency attenuates PAH development by means of reductions in AKT1.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: Tissues from animal pulmonary hypertension models as well as human pulmonary artery endothelial cells from patients with PAH exhibited increased vascular UCHL1 staining and protein expression. Exposure to LDN57444, a UCHL1-specific inhibitor, reduced human pulmonary artery endothelial cell and smooth muscle cell proliferation. Across 3 preclinical PAH models, LDN57444-exposed animals, <i>Uchl1</i> knockout rats (<i>Uchl1</i><sup>-/-</sup>), and conditional <i>Uchl1</i> knockout mice (<i>Tie2Cre-Uchl1</i><sup><i>fl/fl</i></sup>) demonstrated reduced right ventricular hypertrophy, right ventricular systolic pressures, and obliterative vascular remodeling. Lungs and pulmonary artery endothelial cells isolated from <i>Uchl1</i><sup>-/-</sup> animals exhibited reduced total and activated Akt with increased ubiquitinated Akt levels. UCHL1-silenced human pulmonary artery endothelial cells displayed reduced lysine(K)63-linked and increased K48-linked AKT1 levels.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: Supporting experimental data, we found that rs9321, a variant in a GC-enriched region of the <i>UCHL1</i> gene, is associated with reduced methylation (n=5133), increased <i>UCHL1</i> gene expression in lungs (n=815), and reduced cardiac index in patients (n=796). In addition, <i>Gadd45α</i> (an established demethylating gene) knockout mice (<i>Gadd45α</i><sup>-/-</sup>) exhibited reduced lung vascular UCHL1 and AKT1 expression along with attenuated hypoxic pulmonary hypertension.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: Our findings suggest that UCHL1 deficiency results in PAH attenuation by means of reduced AKT1, highlighting a novel therapeutic pathway in PAH.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38695173/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240504001123&v=2.18.0.post9+e462414">38695173</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.123.065304>10.1161/CIRCULATIONAHA.123.065304</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38695173</guid>
<pubDate>Thu, 02 May 2024 06:00:00 -0400</pubDate>
<dc:creator>Haiyang Tang</dc:creator>
<dc:creator>Akash Gupta</dc:creator>
<dc:creator>Seth A Morrisroe</dc:creator>
<dc:creator>Changlei Bao</dc:creator>
<dc:creator>Tae-Hwi Schwantes-An</dc:creator>
<dc:creator>Geetanjali Gupta</dc:creator>
<dc:creator>Shuxin Liang</dc:creator>
<dc:creator>Yanan Sun</dc:creator>
<dc:creator>Aiai Chu</dc:creator>
<dc:creator>Ang Luo</dc:creator>
<dc:creator>Venkateswaran Ramamoorthi Elangovan</dc:creator>
<dc:creator>Shreya Sangam</dc:creator>
<dc:creator>Yinan Shi</dc:creator>
<dc:creator>Samisubbu R Naidu</dc:creator>
<dc:creator>Jia-Rong Jheng</dc:creator>
<dc:creator>Sultan Ciftci-Yilmaz</dc:creator>
<dc:creator>Noel A Warfel</dc:creator>
<dc:creator>Louise Hecker</dc:creator>
<dc:creator>Sumegha Mitra</dc:creator>
<dc:creator>Anna W Coleman</dc:creator>
<dc:creator>Katie A Lutz</dc:creator>
<dc:creator>Michael W Pauciulo</dc:creator>
<dc:creator>Yen-Chun Lai</dc:creator>
<dc:creator>Ali Javaheri</dc:creator>
<dc:creator>Rohan Dharmakumar</dc:creator>
<dc:creator>Wen-Hui Wu</dc:creator>
<dc:creator>Daniel P Flaherty</dc:creator>
<dc:creator>Jason H Karnes</dc:creator>
<dc:creator>Sandra Breuils-Bonnet</dc:creator>
<dc:creator>Olivier Boucherat</dc:creator>
<dc:creator>Sebastien Bonnet</dc:creator>
<dc:creator>Jason X-J Yuan</dc:creator>
<dc:creator>Jeffrey R Jacobson</dc:creator>
<dc:creator>Julio D Duarte</dc:creator>
<dc:creator>William C Nichols</dc:creator>
<dc:creator>Joe G N Garcia</dc:creator>
<dc:creator>Ankit A Desai</dc:creator>
<dc:date>2024-05-02</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Deficiency of the Deubiquitinase UCHL1 Attenuates Pulmonary Arterial Hypertension</dc:title>
<dc:identifier>pmid:38695173</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.123.065304</dc:identifier>
</item>
<item>
<title>Lower extremity arterial disease vs. coronary artery disease: mortality differences after revascularization</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38693795/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240504001123&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: Mortality risk was almost three-fold higher in patients undergoing revascularization for LEAD than in those with CAD. The excessive mortality was considerably attributable to inter-group differences in baseline characteristics, including potentially clinically or socially modifiable factors.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 May 2:ehae207. doi: 10.1093/eurheartj/ehae207. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND AND AIMS: Patients undergoing revascularization for lower extremity arterial disease (LEAD) may face a higher risk of mortality than those with coronary artery disease (CAD). This study aimed to characterize the difference in mortality risk between patients undergoing revascularization for LEAD and CAD and identify associated factors.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: The 1-year database of 10 754 patients undergoing revascularization for CAD (n = 6349) and LEAD (n = 4405) was analysed. Poisson regression models were used to characterize interpopulation differences in mortality, adjusting for baseline clinical features, including age, sex, polyvascular disease, comorbidities, medications, and vulnerabilities.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: Individuals with LEAD were older, were more likely to have polyvascular disease, had more comorbidities, and received fewer cardioprotective drugs than those with CAD. Vulnerabilities remained more common in the LEAD group even after adjusting for these clinical features. The crude risk ratio of mortality incidence for LEAD vs. CAD was 2.91 (95% confidence interval, 2.54-3.34), attenuated to 2.14 (1.83-2.50) after controlling for age, sex, and polyvascular disease. The percentage attenuation in the excessive mortality associated with LEAD was 29%. The stepwise addition of comorbidities, medications, and vulnerabilities as adjusting factors attenuated the incidence risk ratio to 1.48 (1.26-1.72), 1.33 (1.12-1.58), and 1.17 (0.98-1.39), respectively, and increased the percentage attenuation to 64%, 73%, and 86%, respectively.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: Mortality risk was almost three-fold higher in patients undergoing revascularization for LEAD than in those with CAD. The excessive mortality was considerably attributable to inter-group differences in baseline characteristics, including potentially clinically or socially modifiable factors.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38693795/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240504001123&v=2.18.0.post9+e462414">38693795</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae207>10.1093/eurheartj/ehae207</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38693795</guid>
<pubDate>Thu, 02 May 2024 06:00:00 -0400</pubDate>
<dc:creator>Mitsuyoshi Takahara</dc:creator>
<dc:creator>Yoshimitsu Soga</dc:creator>
<dc:creator>Osamu Iida</dc:creator>
<dc:date>2024-05-02</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Lower extremity arterial disease vs. coronary artery disease: mortality differences after revascularization</dc:title>
<dc:identifier>pmid:38693795</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae207</dc:identifier>
</item>
<item>
<title>The Rise of 2 Interacting Subspecialties in Cardiology: Cardiometabolic Diseases and the Microcirculation</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38692831/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240504001123&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 May 7;83(18):1821-1823. doi: 10.1016/j.jacc.2024.03.397.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38692831/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240504001123&v=2.18.0.post9+e462414">38692831</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.03.397>10.1016/j.jacc.2024.03.397</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38692831</guid>
<pubDate>Wed, 01 May 2024 06:00:00 -0400</pubDate>
<dc:creator>Viviany R Taqueti</dc:creator>
<dc:creator>Valentin Fuster</dc:creator>
<dc:date>2024-05-01</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>The Rise of 2 Interacting Subspecialties in Cardiology: Cardiometabolic Diseases and the Microcirculation</dc:title>
<dc:identifier>pmid:38692831</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.03.397</dc:identifier>
</item>
<item>
<title>Management of Severe Mitral Regurgitation in Patients With Acute Myocardial Infarction: JACC Focus Seminar 2/5</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38692830/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240504001123&amp;v=2.18.0.post9+e462414
      <description>Severe acute mitral regurgitation after myocardial infarction includes partial and complete papillary muscle rupture or functional mitral regurgitation. Although its incidence is &lt;1%, mitral regurgitation after acute myocardial infarction frequently causes hemodynamic instability, pulmonary edema, and cardiogenic shock. Medical management has the worst prognosis, and mortality has not changed in decades. Surgery represents the gold standard, but it is associated with high rates of morbidity and...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 May 7;83(18):1799-1817. doi: 10.1016/j.jacc.2023.09.840.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Severe acute mitral regurgitation after myocardial infarction includes partial and complete papillary muscle rupture or functional mitral regurgitation. Although its incidence is &lt;1%, mitral regurgitation after acute myocardial infarction frequently causes hemodynamic instability, pulmonary edema, and cardiogenic shock. Medical management has the worst prognosis, and mortality has not changed in decades. Surgery represents the gold standard, but it is associated with high rates of morbidity and mortality. Recently, transcatheter interventions have opened a new door for management that may improve survival. Mechanical circulatory support restores vital organ perfusion and offers the opportunity for a steadier surgical repair. This review focuses on the diagnosis and the interventional management, both surgical and transcatheter, with a glance on future perspectives to enhance patient management and eventually decrease mortality.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38692830/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240504001123&v=2.18.0.post9+e462414">38692830</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2023.09.840>10.1016/j.jacc.2023.09.840</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38692830</guid>
<pubDate>Wed, 01 May 2024 06:00:00 -0400</pubDate>
<dc:creator>Rodrigo Estévez-Loureiro</dc:creator>
<dc:creator>Roberto Lorusso</dc:creator>
<dc:creator>Maurizio Taramasso</dc:creator>
<dc:creator>Gianluca Torregrossa</dc:creator>
<dc:creator>Annapoorna Kini</dc:creator>
<dc:creator>Pedro R Moreno</dc:creator>
<dc:date>2024-05-01</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Management of Severe Mitral Regurgitation in Patients With Acute Myocardial Infarction: JACC Focus Seminar 2/5</dc:title>
<dc:identifier>pmid:38692830</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2023.09.840</dc:identifier>
</item>
<item>
<title>Right Ventricular Myocardial Infarction-A Tale of Two Ventricles: JACC Focus Seminar 1/5</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38692829/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240504001123&amp;v=2.18.0.post9+e462414
      <description>Right ventricular infarction (RVI) complicates 50% of cases of acute inferior ST-segment elevation myocardial infarction, and is associated with high in-hospital morbidity and mortality. Ischemic right ventricular (RV) systolic dysfunction decreases left ventricular preload delivery, resulting in low-output hypotension with clear lungs, and disproportionate right heart failure. RV systolic performance is generated by left ventricular contractile contributions mediated by the septum. Augmented...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 May 7;83(18):1779-1798. doi: 10.1016/j.jacc.2023.09.839.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Right ventricular infarction (RVI) complicates 50% of cases of acute inferior ST-segment elevation myocardial infarction, and is associated with high in-hospital morbidity and mortality. Ischemic right ventricular (RV) systolic dysfunction decreases left ventricular preload delivery, resulting in low-output hypotension with clear lungs, and disproportionate right heart failure. RV systolic performance is generated by left ventricular contractile contributions mediated by the septum. Augmented right atrial contraction optimizes RV performance, whereas very proximal occlusions induce right atrial ischemia exacerbating hemodynamic compromise. RVI is associated with vagal mediated bradyarrhythmias, both during acute occlusion and abruptly with reperfusion. The ischemic dilated RV is also prone to malignant ventricular arrhythmias. Nevertheless, RV is remarkably resistant to infarction. Reperfusion facilitates RV recovery, even after prolonged occlusion and in patients with severe shock. However, in some cases hemodynamic compromise persists, necessitating pharmacological and mechanical circulatory support with dedicated RV assist devices as a "bridge to recovery."</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38692829/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240504001123&v=2.18.0.post9+e462414">38692829</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2023.09.839>10.1016/j.jacc.2023.09.839</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38692829</guid>
<pubDate>Wed, 01 May 2024 06:00:00 -0400</pubDate>
<dc:creator>James A Goldstein</dc:creator>
<dc:creator>Stamatios Lerakis</dc:creator>
<dc:creator>Pedro R Moreno</dc:creator>
<dc:date>2024-05-01</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Right Ventricular Myocardial Infarction-A Tale of Two Ventricles: JACC Focus Seminar 1/5</dc:title>
<dc:identifier>pmid:38692829</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2023.09.839</dc:identifier>
</item>
<item>
<title>Can Plaque Imaging Improve Risk Assessment Among Individuals With Elevated Lp(a)?</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38692828/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240504001123&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 May 7;83(18):1756-1759. doi: 10.1016/j.jacc.2024.03.386.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38692828/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240504001123&v=2.18.0.post9+e462414">38692828</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.03.386>10.1016/j.jacc.2024.03.386</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38692828</guid>
<pubDate>Wed, 01 May 2024 06:00:00 -0400</pubDate>
<dc:creator>Ron Blankstein</dc:creator>
<dc:creator>Arthur Shiyovich</dc:creator>
<dc:date>2024-05-01</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Can Plaque Imaging Improve Risk Assessment Among Individuals With Elevated Lp(a)?</dc:title>
<dc:identifier>pmid:38692828</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.03.386</dc:identifier>
</item>
<item>
<title>Association of Lipoprotein(a) Levels With Myocardial Infarction in Patients With Low-Attenuation Plaque</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38692827/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240504001123&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: Elevated Lp(a) augmented the risk of MI during 8 years of follow-up, especially in patients with LAP identified by CCTA. The presence of LAP could reinforce the relationship between Lp(a) and future MI occurrence.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 May 7;83(18):1743-1755. doi: 10.1016/j.jacc.2024.03.367.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: Lipoprotein(a) (Lp[a]) is associated with an increased risk of myocardial infarction (MI). However, the mechanism underlying this association has yet to be fully elucidated.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">OBJECTIVES: This multicenter study aimed to investigate whether association between Lp(a) and MI risk is reinforced by the presence of low-attenuation plaque (LAP) identified by coronary computed tomography angiography (CCTA).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: In a derivation cohort, a total of 5,607 patients with stable chest pain suspected of coronary artery disease who underwent CCTA and Lp(a) measurement were prospectively enrolled. In validation cohort, 1,122 patients were retrospectively collected during the same period. High Lp(a) was defined as Lp(a) ≥50 mg/dL. The primary endpoint was a composite of time to fatal or nonfatal MI. Associations were estimated using multivariable Cox proportional hazard models.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: During a median follow-up of 8.2 years (Q1-Q3: 7.2-9.3 years), the elevated Lp(a) levels were associated with MI risk (adjusted HR [aHR]: 1.91; 95% CI: 1.46-2.49; P &lt; 0.001). There was a significant interaction between Lp(a) and LAP (P<sub>interaction</sub> &lt;0.001) in relation to MI risk. When stratified by the presence or absence of LAP, Lp(a) was associated with MI in patients with LAP (aHR: 3.03; 95% CI: 1.92-4.76; P &lt; 0.001). Mediation analysis revealed that LAP mediated 73.3% (P &lt; 0.001) for the relationship between Lp(a) and MI. The principal findings remained unchanged in the validation cohort.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: Elevated Lp(a) augmented the risk of MI during 8 years of follow-up, especially in patients with LAP identified by CCTA. The presence of LAP could reinforce the relationship between Lp(a) and future MI occurrence.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38692827/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240504001123&v=2.18.0.post9+e462414">38692827</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.03.367>10.1016/j.jacc.2024.03.367</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38692827</guid>
<pubDate>Wed, 01 May 2024 06:00:00 -0400</pubDate>
<dc:creator>Meng-Meng Yu</dc:creator>
<dc:creator>Ming-Liang Wang</dc:creator>
<dc:creator>Jin-Jin Wang</dc:creator>
<dc:creator>Bo-Li Lin</dc:creator>
<dc:creator>Xin Zhao</dc:creator>
<dc:creator>Xin-Wei Tao</dc:creator>
<dc:creator>Yin-Yin Chen</dc:creator>
<dc:creator>Peng-Yang Li</dc:creator>
<dc:creator>Jing-Kun Zhang</dc:creator>
<dc:creator>Jun-Bo Ge</dc:creator>
<dc:creator>Hang Jin</dc:creator>
<dc:creator>Meng-Su Zeng</dc:creator>
<dc:date>2024-05-01</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Association of Lipoprotein(a) Levels With Myocardial Infarction in Patients With Low-Attenuation Plaque</dc:title>
<dc:identifier>pmid:38692827</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.03.367</dc:identifier>
</item>
<item>
<title>Clonal Hematopoiesis Among Patients With Asymptomatic Carotid Stenosis Compounds Risk of Cardiovascular Death</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38692826/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240504001123&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 May 7;83(18):1728-1730. doi: 10.1016/j.jacc.2024.03.389.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38692826/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240504001123&v=2.18.0.post9+e462414">38692826</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.03.389>10.1016/j.jacc.2024.03.389</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38692826</guid>
<pubDate>Wed, 01 May 2024 06:00:00 -0400</pubDate>
<dc:creator>Pradeep Natarajan</dc:creator>
<dc:creator>Tiffany R Bellomo</dc:creator>
<dc:date>2024-05-01</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Clonal Hematopoiesis Among Patients With Asymptomatic Carotid Stenosis Compounds Risk of Cardiovascular Death</dc:title>
<dc:identifier>pmid:38692826</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.03.389</dc:identifier>
</item>
<item>
<title>Combined Effects of Clonal Hematopoiesis and Carotid Stenosis on Cardiovascular Mortality</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38692825/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240504001123&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: CH status in combination with the extent of carotid atherosclerosis jointly predict long-term mortality. Determination of CH can provide additional prognostic information in patients with asymptomatic carotid atherosclerosis.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 May 7;83(18):1717-1727. doi: 10.1016/j.jacc.2024.02.043.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: The expansion of hematopoietic stem cells caused by acquired somatic mutations (clonal hematopoiesis [CH]) is a novel cardiovascular risk factor. The prognostic value of CH in patients with carotid atherosclerosis remains to be evaluated.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">OBJECTIVES: This study assessed the prognostic significance of CH in patients with atherosclerosis as detected by ultrasound of the carotid artery.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: We applied deep sequencing of selected genomic regions within the genes DNMT3A, TET2, ASXL1, and JAK2 to screen for CH in 968 prospectively collected patients with asymptomatic carotid atherosclerosis evaluated by duplex sonography.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: We detected clonal markers at variant allele frequency ≥2% in 133 (13.7%) of 968 patients (median age 69.2 years), with increasing prevalence at advanced age. Multivariate analyses including age and established cardiovascular risk factors revealed overall presence of CH to be significantly associated with increased risk of cardiovascular death (HR: 1.50; 95% CI: 1.12-2.00; P = 0.007), reflected also at the single gene level. The effect of CH was more pronounced in older patients and independent of the patients' inflammatory status as measured by high-sensitivity C-reactive protein. Simultaneous assessment of CH and degree of carotid stenosis revealed combined effects on cardiovascular mortality, depicted by a superior risk for patients with >;50% stenosis and concomitant CH (adjusted HR: 1.60; 95% CI: 1.08-2.38; P = 0.020).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: CH status in combination with the extent of carotid atherosclerosis jointly predict long-term mortality. Determination of CH can provide additional prognostic information in patients with asymptomatic carotid atherosclerosis.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38692825/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240504001123&v=2.18.0.post9+e462414">38692825</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.02.043>10.1016/j.jacc.2024.02.043</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38692825</guid>
<pubDate>Wed, 01 May 2024 06:00:00 -0400</pubDate>
<dc:creator>Roland Jäger</dc:creator>
<dc:creator>Matthias Hoke</dc:creator>
<dc:creator>Florian J Mayer</dc:creator>
<dc:creator>Stefanie Boden</dc:creator>
<dc:creator>Cornelia Englisch</dc:creator>
<dc:creator>Cihan Ay</dc:creator>
<dc:creator>Robert Kralovics</dc:creator>
<dc:creator>Christoph J Binder</dc:creator>
<dc:date>2024-05-01</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Combined Effects of Clonal Hematopoiesis and Carotid Stenosis on Cardiovascular Mortality</dc:title>
<dc:identifier>pmid:38692825</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.02.043</dc:identifier>
</item>
<item>
<title>Deep Learning-Based Assessment of Built Environment From Satellite Images and Cardiometabolic Disease Prevalence</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38691380/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240504001123&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS AND RELEVANCE: In this cross-sectional study, a significant portion of cardiometabolic disease prevalence was associated with GSI-based built environment using convolutional neural networks.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">JAMA Cardiol. 2024 May 1. doi: 10.1001/jamacardio.2024.0749. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">IMPORTANCE: Built environment plays an important role in development of cardiovascular disease. Large scale, pragmatic evaluation of built environment has been limited owing to scarce data and inconsistent data quality.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">OBJECTIVE: To investigate the association between image-based built environment and the prevalence of cardiometabolic disease in urban cities.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">DESIGN, SETTING, AND PARTICIPANTS: This cross-sectional study used features extracted from Google satellite images (GSI) to measure the built environment and link them with prevalence of cardiometabolic disease. Convolutional neural networks, light gradient-boosting machines, and activation maps were used to assess the association with health outcomes and identify feature associations with coronary heart disease (CHD), stroke, and chronic kidney disease (CKD). The study obtained aerial images from GSI covering census tracts in 7 cities (Cleveland, Ohio; Fremont, California; Kansas City, Missouri; Detroit, Michigan; Bellevue, Washington; Brownsville, Texas; and Denver, Colorado). The study used census tract-level data from the US Centers for Disease Control and Prevention's 500 Cities project. The data were originally collected from the Behavioral Risk Factor Surveillance System that surveyed people 18 years and older across the country. Analyses were conducted from February to December 2022.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">EXPOSURES: GSI images of built environment and cardiometabolic disease prevalence.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">MAIN OUTCOMES AND MEASURES: Census tract-level estimated prevalence of CHD, stroke, and CKD based on image-based built environment features.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: The study obtained 31 786 aerial images from GSI covering 789 census tracts. Built environment features extracted from GSI using machine learning were associated with prevalence of CHD (R2 = 0.60), stroke (R2 = 0.65), and CKD (R2 = 0.64). The model performed better at distinguishing differences between cardiometabolic prevalence between cities than within cities (eg, highest within-city R2 = 0.39 vs between-city R2 = 0.64 for CKD). Addition of GSI features both outperformed and improved the model that only included age, sex, race, income, education, and composite indices for social determinants of health (R2 = 0.83 vs R2 = 0.76 for CHD; P &lt;.001). Activation maps from the features revealed certain health-related built environment such as roads, highways, and railroads and recreational facilities such as amusement parks, arenas, and baseball parks.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS AND RELEVANCE: In this cross-sectional study, a significant portion of cardiometabolic disease prevalence was associated with GSI-based built environment using convolutional neural networks.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38691380/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240504001123&v=2.18.0.post9+e462414">38691380</a> | DOI:<a href=https://doi.org/10.1001/jamacardio.2024.0749>10.1001/jamacardio.2024.0749</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38691380</guid>
<pubDate>Wed, 01 May 2024 06:00:00 -0400</pubDate>
<dc:creator>Zhuo Chen</dc:creator>
<dc:creator>Jean-Eudes Dazard</dc:creator>
<dc:creator>Yassin Khalifa</dc:creator>
<dc:creator>Issam Motairek</dc:creator>
<dc:creator>Catherine Kreatsoulas</dc:creator>
<dc:creator>Sanjay Rajagopalan</dc:creator>
<dc:creator>Sadeer Al-Kindi</dc:creator>
<dc:date>2024-05-01</dc:date>
<dc:source>JAMA cardiology</dc:source>
<dc:title>Deep Learning-Based Assessment of Built Environment From Satellite Images and Cardiometabolic Disease Prevalence</dc:title>
<dc:identifier>pmid:38691380</dc:identifier>
<dc:identifier>doi:10.1001/jamacardio.2024.0749</dc:identifier>
</item>
<item>
<title>Wide Complex Tachycardia in a Middle-Aged Woman With Diarrhea</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38691373/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240504001123&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">JAMA Cardiol. 2024 May 1. doi: 10.1001/jamacardio.2024.0744. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38691373/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240504001123&v=2.18.0.post9+e462414">38691373</a> | DOI:<a href=https://doi.org/10.1001/jamacardio.2024.0744>10.1001/jamacardio.2024.0744</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38691373</guid>
<pubDate>Wed, 01 May 2024 06:00:00 -0400</pubDate>
<dc:creator>Matthew G Peters</dc:creator>
<dc:creator>Nachiket Apte</dc:creator>
<dc:creator>Dinesh K Kalra</dc:creator>
<dc:date>2024-05-01</dc:date>
<dc:source>JAMA cardiology</dc:source>
<dc:title>Wide Complex Tachycardia in a Middle-Aged Woman With Diarrhea</dc:title>
<dc:identifier>pmid:38691373</dc:identifier>
<dc:identifier>doi:10.1001/jamacardio.2024.0744</dc:identifier>
</item>





























</channel>
</rss>